Ophthal Medical News about Bimatoprost

Your Unread Messages

See All

Hello, Mary O'connor
Manage E-mail | Logout

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Doctors and the DEA Free full text

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Bimatoprost - a review
Expert Opinion in Pharmacotherapy, 11/06/09

Patil JA et al. – Bimatoprost is a synthetic prostamide analog that is efficacious in the treatment of open–angle glaucoma, ocular hypertension and other forms of glaucoma. It reduces intraocular pressure (IOP) by increasing uveoscleral and trabecular outflow. When used as a 0.03% topical preparation once daily, it demonstrates sustained lowering of IOP of 7 – 8 mmHg over a 24–h period. The drug has been found to be more effective than timolol. In some studies it has shown greater ability to lower IOP when compared with other prostaglandin analogs; whereas in others all three clinically used prostaglandin analogs were found to be equally effective. It shows good IOP reduction when used in combination with other glaucoma medications. A common side effect includes mild conjunctival hyperemia, which is generally reversible. Other side effects include periorbital pigmentation, discomfort, ocular surface hyperemia and skin changes. Pharmacoeconomic data indicate that bimatoprost is cost effective in the treatment of open–angle glaucoma.

<< Previous
Management of intraoperative floppy-iris syndrome–associated iris...

Next >>
Simplified technique for combined silicone oil removal during...

Update and commentary on the pro-drug bimatoprost and a putative prostamide receptor
Expert Review of Ophthalmology, 10/21/09 Relevance Score: 89%

Bilateral Deepening of Upper Lid Sulcus From Topical Bimatoprost Therapy
Journal of Ocular Pharmacology and Therapeutics, 11/04/09 Relevance Score: 88%

A Comparison of Bimatoprost 0.03% Versus the Fixed-Combination of Latanotoprost 0.005% and Timolol 0.5% in Adult Patients With Elevated Intraocular Pressure: An Eight-Week, Randomized, Open-Label Trial
Journal of Ocular Pharmacology and Therapeutics, 11/09/09 Relevance Score: 83%